Prognostic value of the preoperative immunological profile in patients with glioblastoma

Surgical Neurology International

Volumn 5, Issue Supplement, 2014, Pages

  Gousias, Konstantinos ^a,b   Voulgaris, Spiridon ^b   Vartholomatos, Georgios ^b   Voulgari, Paraskevi ^b   Kyritsis, Athanasios P ^b   Markou, Markella ^c  

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^c Landschaftsverband Rheinland Klinik   (Germany)

Author keywords

CD4+ cells; Glioblastoma multiforme; IL 2; Overall survival; Serum

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 2; TEMOZOLOMIDE;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPILEPSY; FLOW CYTOMETRY; GLIOBLASTOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNODIFFUSION; IMMUNOSUPPRESSIVE TREATMENT; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; TUMOR VOLUME;

EID: 84916208718     PISSN: None     EISSN: 21527806     Source Type: Journal    
DOI: 10.4103/2152-7806.134104     Document Type: Article

References (32)

1. Balza E, Carnemolla B, Mortara L, Castellani P, Soncini D, Accolla RS, et al. Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFalpha. Intl J Cancer 2010;127:101-10.
2. Bauchet L, Mathieu-Daude H, Fabbro-Peray P, Rigau V, Fabbro M, Chinot O, et al. Oncological patterns of care and outcome for 952 patients with newly diagnosed glioblastoma in 2004. Neuro Oncol 2010;12:725-35.
3. Blaylock RL. Immunoexcitatory mechanisms in glioma proliferation, invasion and occasional metastasis. Surg Neurol Int 2013;4:15.
4. Blaylock RL. Immunology primer for neurosurgeons and neurologists part I: Basic principles of immunology. Surg Neurol Int 2013;4:14.
5. Blaylock RL, Maroon J. Natural plant products and extracts that reduce immunoexcitotoxicity-associated neurodegeneration and promote repair within the central nervous system. Surg Neurol Int 2012;3:19.
6. Chaicana K, Parker S, Olivi A. Quinones-Hinojosa A. A proposed classification system that projects outcome based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 2010;112:997-1004.
7. Cid MC, Campo E, Ercilla G, Palacin A, Vilaseca J, Villalta J, et al. Immunohistochemical analysis of lymphoid and macrophage cell subsets and their immunological activation markers in temporal arteritis. Influence of corticosteroid treatment. Arthritis Rheum 1989;32:884-93.
8. Delves PJ, Martin SJ, Burton DR, Roitt IM, Editors. Roitt's Essential Immunology. 12th ed. USA: Wiley-Blackwell; 2011.
9. Dimitrov S, Benedict C, Heutling D, Westermann J, Born J, Lange T. Cortisol and epinephrine control opposing circadian rhythms in T cell subsets. Blood 2009;113:5134-43.
10. Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol 1999;100:216-32.
11. El Andaloussi A, Han Y, Lesniak MS. Prolongation of survival following depletion of CD4+CD25+regulatory T cells in mice with experimental brain tumors. J Neurosurg 2006;105:430-7.
12. Fecci PE, Mitschell DA, Whitesides JF, Xie W, Friedman AH, Archer GE, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302.
13. Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A, et al. Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol 2010;226:136-42.
14. Gousias K, Markou M, Voulgaris S, Goussia A, Voulgari P, Bai M, et al. Descriptive epidemiology of cerebral gliomas in Nortwest Greece and study of potential predisposing factors, 2005-2007. Neuroepidemiology 2009;33:89-95.
15. Gousias K, Von Ruecker A, Voulgari P, Simon M. Phenotypical analysis, relation to malignancy and prognostic relevance of ICOS+T regulatory and dendritic cells in patients with gliomas. J Neuroimmunol 2013;264:84-90.
16. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 2010;120:707-18.
17. Hegi ME, Liu L, Herman JG, Stupp R, Wick W, Weller M, et al. Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 2008;26:4189-99.
18. Helseth R, Helseth E, Johannesen TB, Langberg CW, Lote K, Ronning P, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand 2010;122:159-67.
19. Hughes MA, Parisi M, Grossman S, Kleinberg L. Primary brain tumors treated with steroids and radiotherapy: Low CD4 counts and risk of infection. Int J Radiat Oncol Biol Phys 2005;62:1423-6.
20. Li W, Graeber MB. The molecular profile of microglia under the influence of glioma. Neuro Oncol 2012;14:958-78.
21. Lichtor T, Glick RP, Tarlock K, Moffett S, Mouw E, Cohen EP. Application of interleukin-2-sekreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors. Cancer Gene Ther 2002;9:464-9.
22. Milasiene V, Stratilatovas E, Norkiene V. The importance of T-lymphocyte subsets on overall survival of colorectal and gastric cancer patients. Medicina (Kaunas) 2007;43:548-54.
23. Mineo JF, Bordom A, Baroncini M, Ramirez C, Maurage CA, Blond S, et al. Prognostic factors of survival time in patients with glioblastoma multiforme: A multivariate analysis of 340 patients. Acta Neurochir (Wien) 2007;149:245-53.
24. Mitchell DA, Fecci PE, Sampson JH. Immunotherapy of malignant brain tumors. Immunol Rev 2008;222:70-100.
25. Pedretti M, Verpelli C, Marlind J, Bertani G, Sala C, Neri D, et al. Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer 2010;103:827-36.
26. Peracoli MT, Montelli TC, Scares AM, Farise-Fortes MR, Alquati SAB, Ueda A, et al. Immunological alterations in patients with primary tumors in central nervous system. Arq Neuropsiquiatr 1999;57:539-46.
27. Spagnolo A, Glick RP, Lin H, Cohen EP, Feinstein DL, Lichtor T. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-. thiazolidinedione agonists and interleukin-2-sekreting syngeneic/allogeneic fibroblasts. J Neurosurg 2007;106:299-305.
28. Stummer W, Reulen HJ, Meinel T, Pichlmeier U, Schumacher W, Tonn JC, et al. Extent of resection and survival in glioblastoma multiforme: Identification of and adjustment for bias. Neurosurgery 2008;62:564-76.
29. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
30. Available from: http://www.cbtrus.com. [Last accessed on 2014 Mar. 05].
31. Available from: http://www.who.int/hiv/pub/guidelines. [Last accessed on 2014 Mar. 05].
32. Yamasaki T, Kikuchi H, Yamashita J, Handa H, Kuwata S, Taguchi M, et al. Immunoregulatory effects of interleukin 2 and interferon on syngeneic murine malignant glioma-specific cytotoxic T-lymphocytes. Cancer Res 1988;48:2981-7.